ONCOCYTE CORP's ticker is OCX and the CUSIP is 68235C107. A total of 95 filers reported holding ONCOCYTE CORP in Q2 2021. The put-call ratio across all filers is 0.41 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2023 | $73,600 | +10.4% | 207,675 | 0.0% | 0.06% | -1.8% |
Q4 2022 | $66,643 | -83.8% | 207,675 | -63.1% | 0.06% | -83.9% |
Q3 2022 | $411,000 | -20.7% | 563,350 | -2.2% | 0.35% | -13.4% |
Q2 2022 | $518,000 | -39.8% | 575,750 | -0.4% | 0.41% | -26.8% |
Q1 2022 | $861,000 | -31.4% | 578,150 | 0.0% | 0.56% | -26.1% |
Q4 2021 | $1,255,000 | -38.9% | 578,150 | +0.2% | 0.76% | -40.8% |
Q3 2021 | $2,055,000 | -15.1% | 577,200 | +36.9% | 1.28% | -12.0% |
Q2 2021 | $2,421,000 | +10.1% | 421,775 | -0.5% | 1.45% | -8.3% |
Q1 2021 | $2,199,000 | +117.1% | 423,775 | 0.0% | 1.58% | +102.9% |
Q4 2020 | $1,013,000 | +217.6% | 423,775 | +84.7% | 0.78% | +181.6% |
Q3 2020 | $319,000 | -22.6% | 229,425 | +6.4% | 0.28% | -31.6% |
Q2 2020 | $412,000 | -22.1% | 215,625 | 0.0% | 0.40% | -40.2% |
Q1 2020 | $529,000 | +32.9% | 215,625 | +21.9% | 0.68% | +74.5% |
Q4 2019 | $398,000 | – | 176,878 | – | 0.39% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
BROADWOOD CAPITAL INC | 23,353,697 | $17,048,000 | 1.30% |
AWM Investment Company, Inc. | 7,746,557 | $5,655,000 | 0.86% |
PURA VIDA INVESTMENTS, LLC | 18,056,274 | $13,181,000 | 0.76% |
Defender Capital, LLC. | 2,551,980 | $1,883,000 | 0.74% |
Penbrook Management LLC | 563,350 | $411,000 | 0.35% |
ACT CAPITAL MANAGEMENT, LLC | 330,000 | $241,000 | 0.33% |
CALIBER WEALTH MANAGEMENT, LLC | 75,120 | $55,000 | 0.04% |
Fort Sheridan Advisors LLC | 135,000 | $99,000 | 0.03% |
Orbimed Advisors | 1,882,768 | $1,374,000 | 0.03% |
WEALTH EFFECTS LLC | 51,000 | $37,000 | 0.02% |